# Onkure Therapeutics, Inc. (OKUR)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001637715 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001637715))
- Full page: https://inspectstocks.com/stocks/okur
- Data as of: price 2026-09-28; newest filing used 2026-08-04; latest fiscal period ended 2026-06-30

## Grade

**C** on the balance-sheet rubric used for lenders, 2 of 4 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -$58.7M |  |
| Earnings growing overall | passed | -$58.7M | -$61.2M |
| Earnings growing recently | passed | -$58.7M | -$59.5M |
| Earns well on its assets | failed | -32.7% |  |
| Book value per share growing | not answerable | $4.16 | -$2.22 |

Business quality (the + / − mark): 1 of 2 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Good return on equity | failed | -104.5% |  |
| Debt under control | passed | 0.01 |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $0.00 |
| Net income, trailing twelve months | -$58.7M |
| Free cash flow, trailing twelve months | -$47.9M |
| Return on equity | -104.5% |
| Debt to equity | 0.01 |
| Diluted EPS, trailing twelve months | -$3.50 |
| Share price | $2.76 |
| Market value | $111.6M |

## More on this company

- [Overview](https://inspectstocks.com/stocks/okur)
- [Financial statements](https://inspectstocks.com/stocks/okur/financials)
- [Competitors](https://inspectstocks.com/stocks/okur/peers)
- [Earnings](https://inspectstocks.com/stocks/okur/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.